Illumina, Inc. (NASDAQ:ILMN) Shares Bought by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lifted its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 2,057.5% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 922,281 shares of the life sciences company's stock after purchasing an additional 879,533 shares during the period. Assenagon Asset Management S.A. owned 0.58% of Illumina worth $73,174,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Golden State Wealth Management LLC purchased a new stake in shares of Illumina in the 4th quarter worth $32,000. Fourth Dimension Wealth LLC purchased a new stake in Illumina in the 4th quarter worth $40,000. PFS Partners LLC increased its stake in Illumina by 400.0% in the 1st quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock worth $40,000 after buying an additional 400 shares in the last quarter. Assetmark Inc. increased its stake in Illumina by 954.8% in the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after buying an additional 296 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new stake in Illumina in the 4th quarter worth $45,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Trading Down 1.4%

Shares of NASDAQ ILMN traded down $1.20 during midday trading on Friday, hitting $86.93. The company's stock had a trading volume of 1,612,726 shares, compared to its average volume of 2,279,790. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The business's 50 day moving average is $79.08 and its two-hundred day moving average is $102.92. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The firm has a market cap of $13.76 billion, a P/E ratio of -11.32, a price-to-earnings-growth ratio of 1.60 and a beta of 1.32.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.01. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.03 billion. During the same period in the prior year, the business posted $0.98 earnings per share. The company's revenue for the quarter was down 1.4% on a year-over-year basis. As a group, equities research analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on ILMN shares. Morgan Stanley cut their price objective on Illumina from $136.00 to $100.00 and set an "equal weight" rating for the company in a research report on Monday, May 12th. Royal Bank of Canada dropped their price target on Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a research note on Tuesday, April 8th. Canaccord Genuity Group increased their price target on Illumina from $87.00 to $99.00 and gave the company a "hold" rating in a research note on Wednesday. Barclays dropped their price target on Illumina from $100.00 to $77.00 and set an "underweight" rating for the company in a research note on Thursday, April 10th. Finally, Piper Sandler dropped their price target on Illumina from $190.00 to $185.00 and set an "overweight" rating for the company in a research note on Thursday, May 15th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Illumina currently has a consensus rating of "Moderate Buy" and an average price target of $126.94.

Insiders Place Their Bets

In related news, CFO Ankur Dhingra bought 6,100 shares of the company's stock in a transaction on Monday, May 12th. The shares were acquired at an average price of $81.21 per share, with a total value of $495,381.00. Following the transaction, the chief financial officer now owns 24,906 shares of the company's stock, valued at $2,022,616.26. The trade was a 32.44% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.60% of the stock is currently owned by company insiders.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.